Johnson & Johnson to acquire Ollin Biosciences for up to $3.3 billion

Johnson & Johnson (J&J) has entered into a definitive agreement to acquire Ollin Biosciences for $2.2 billion upfront, with additional regulatory and commercial milestone payments of up to approximately $1.125 billion. The transaction will add OLN324, an investigational bispecific antibody in Phase III development for retinal vascular diseases, to J&J’s pharmaceutical pipeline. Completion is expected before the end of 2026, subject to regulatory approvals and customary closing conditions.

The proposed acquisition values Ollin at up to approximately $3.3 billion, including the potential milestone payments. It represents a strategic expansion of J&J’s prescription ophthalmology portfolio, particularly in treatments for wet age-related macular degeneration (wAMD) and diabetic macular edema (DME).

OLN324 targets two pathways involved in retinal disease

OLN324 is designed to inhibit vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang2), two signalling pathways involved in retinal vascular diseases. The investigational antibody is being developed for wAMD and DME, both of which can cause progressive vision loss.

According to Ollin Biosciences, OLN324 combines a smaller molecular format, described as a minibody, with enhanced Ang2 potency. Its development strategy is intended to improve control of retinal fluid and potentially extend the interval between treatments.

The asset was discovered by China-based Innovent Biologics and out-licensed to Ollin for further development. The two companies continue to collaborate on its clinical development. Innovent uses the internal development code IBI324 for the molecule.

Phase Ib JADE study provides early clinical evidence

The clinical evidence supporting the programme includes the randomized Phase Ib JADE study, which compared OLN324 with faricimab, marketed by Roche as Vabysmo. The study enrolled 164 patients in the United States with either DME or wAMD.

Participants received three initial monthly injections of OLN324 at doses of 2 mg or 4 mg, or faricimab at 6 mg. They were subsequently followed for an additional 12 weeks without mandatory treatment, with retreatment permitted according to predefined criteria.

In patients with DME, OLN324 4 mg demonstrated greater reductions in central subfield thickness than faricimab. At Week 20, 93% of patients receiving OLN324 4 mg had completed the follow-up period without retreatment, compared with 89% in the faricimab group.

In wAMD, overall improvements in retinal drying were broadly comparable between treatment groups. However, a prespecified analysis of pigment epithelial detachment (PED) thickness showed a more pronounced effect with OLN324 4 mg. At Week 12, reductions in PED thickness were approximately 50% greater than with faricimab, with the improvements also appearing more durable through Week 20.

Patients receiving OLN324 4 mg demonstrated a numerically greater improvement in best-corrected visual acuity, with a mean difference of 2.2 letters compared with faricimab at Week 20. The proportion completing the follow-up period without retreatment was 82% in the OLN324 4 mg group and 81% in the faricimab group.

No cases of intraocular inflammation were reported in the OLN324 groups during the study, compared with one case in the faricimab group.

These findings should be interpreted in the context of the trial design. JADE was a Phase Ib study primarily designed to assess safety and tolerability, while efficacy measures were exploratory. The results, reported by Ollin, do not establish clinical superiority over faricimab. Larger Phase III studies will be needed to determine whether the observed differences translate into meaningful clinical benefits.

Blackstone to provide $750 million for Phase III development

Alongside the acquisition agreement, J&J has announced a separate development funding arrangement with Blackstone Life Sciences.

Under the proposed arrangement, Blackstone will provide $750 million to J&J over multiple years to fund the Phase III clinical development of OLN324, including programmes in wAMD and DME. In return, Blackstone will be eligible for certain regulatory and sales milestone payments, as well as single-digit royalties.

The funding arrangement is contingent upon completion of the Ollin acquisition.

The $750 million is separate from the acquisition consideration and the potential milestone payments payable to Ollin’s shareholders. The arrangement provides dedicated funding for the late-stage clinical programme while allowing Blackstone to participate in the potential future commercial value of the asset.

Strategic expansion into prescription ophthalmology

The acquisition would broaden J&J’s activities in ophthalmology beyond its established positions in contact lenses, surgical equipment and vision-care technologies. Although the company has a significant presence in eye care, its prescription medicines portfolio has had a more limited position in retinal diseases.

OLN324 would provide an opportunity to enter a competitive market that includes established therapies such as faricimab (Vabysmo), aflibercept products including Eylea, and ranibizumab (Lucentis).

Differentiation will be a central challenge for the programme. OLN324’s smaller molecular format and enhanced Ang2 potency are intended to distinguish it from existing treatments. However, the available Phase Ib evidence is not sufficient to establish a durable efficacy or dosing advantage.

The commercial prospects of OLN324 will depend on the results of Phase III trials, its eventual dosing profile, safety and regulatory outcomes, as well as its ability to demonstrate a meaningful advantage over established therapies.

Next steps

The immediate corporate milestone is completion of the acquisition, which remains subject to regulatory approvals and customary closing conditions. Meanwhile, the global Phase III development programme for OLN324 in DME and wAMD has already advanced to patient recruitment. Following completion of the transaction, J&J will assume responsibility for advancing the programme, supported by the separate $750 million development funding arrangement with Blackstone Life Sciences.

For J&J, the transaction represents a substantial investment in prescription ophthalmology and an opportunity to expand its presence in retinal vascular disease treatments. For OLN324, the decisive test will be whether the early findings from JADE can be reproduced in larger, adequately powered clinical trials.

Until those results become available, the acquisition should be viewed as an investment in clinical potential rather than confirmation of a new standard of care.

POPULAR